Comparison · NCT02436668-deaths
Placebo (Plus Nab-paclitaxel and Gemcitabine) vs Ibrutinib (Plus Nab-paclitaxel and Gemcitabine): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Placebo (Plus Nab-paclitaxel and Gemcitabine) vs Ibrutinib (Plus Nab-paclitaxel and Gemcitabine): deaths from any cause. Trial comparisons, record NCT02436668-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02436668-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.887 | 0.837 | 0.923 | wilson | |
| Risk in group 2 | 0.909 | 0.862 | 0.941 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0219 | -0.081 | 0.0372 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.976 | 0.915 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.787 | 0.417 | 1.49 | log | |
| Number needed to treat, for one fewer death from any cause on Placebo (Plus Nab-paclitaxel and Gemcitabine) than on Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 45.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Placebo (Plus Nab-paclitaxel and Gemcitabine) | Placebo daily in combination with:~Nab-paclitaxel and gemcitabine~Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion | 188 | 212 | EG000 |
| Group 2 | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | Ibrutinib 560 mg (4 x 140 mg capsules) (or placebo) was administered orally once daily beginning on Day 1 of Cycle 1 of the treatment phase, with the first dose of ibrutinib given no more than 72 hours after randomization~Nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 were administered on Days 1, 8, and 15 of each 28-day cycle, each as a 30- to 40-minute intravenous infusion | 189 | 208 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From first dose of study drug up to 30 days after the last dose of study drug
Source ClinicalTrials.gov
Trial
- Title
- Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
- NCT number
- NCT02436668
- Phases
- PHASE3
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Ibrutinib, Gemcitabine, Nab-paclitaxel
- Lead sponsor
- Pharmacyclics LLC.
- Results first posted
- 2020-11-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02436668?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02436668-deaths